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Abstract
Background: Reference values for hematological and biochemical assays in pregnant women and
in newborn infants are based primarily on Caucasian populations. Normative data are limited for
populations in sub-Saharan Africa, especially comparing women with and without HIV infection, and
comparing infants with and without HIV infection or HIV exposure.
Methods: We determined HIV status and selected hematological and biochemical measurements
in women at 20–24 weeks and at 36 weeks gestation, and in infants at birth and 4–6 weeks of age.
All were recruited within a randomized clinical trial of antibiotics to prevent chorioamnionitis-
associated mother-to-child transmission of HIV (HPTN024). We report nearly complete
laboratory data on 2,292 HIV-infected and 367 HIV-uninfected pregnant African women who were
representative of the public clinics from which the women were recruited. Nearly all the HIV-
infected mothers received nevirapine prophylaxis at the time of labor, as did their infants after birth
(always within 72 hours of birth, but typically within just a few hours at the four study sites in
Malawi (2 sites), Tanzania, and Zambia.
Results: HIV-infected pregnant women had lower red blood cell counts, hemoglobin, hematocrit,
and white blood cell counts than HIV-uninfected women. Platelet and monocyte counts were
higher among HIV-infected women at both time points. At the 4–6-week visit, HIV-infected infants
had lower hemoglobin, hematocrit and white blood cell counts than uninfected infants. Platelet
counts were lower in HIV-infected infants than HIV-uninfected infants, both at birth and at 4–6
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weeks of age. At 4–6 weeks, HIV-infected infants had higher alanine aminotransferase measures
than uninfected infants.
Conclusion: Normative data in pregnant African women and their newborn infants are needed to
guide the large-scale HIV care and treatment programs being scaled up throughout the continent.
These laboratory measures will help interpret clinical data and assist in patient monitoring in a sub-
Saharan Africa context.
Trial Registration: nicalTrials.gov Identifier NCT00021671.
Introduction
Hematological parameters are affected by many factors,
including age, sex, diet, recent nutritional status, and con-
sumption of medications or illicit drugs.[1-4] Reference
values for hematological and biochemical assays in preg-
nant women and in infants are based largely on data from
Caucasian populations. Normative data have been
reported from only a few populations living in sub-Saha-
ran Africa.[2,4-10] Fewer studies still highlight expected
values from women and infants with HIV infection or
exposure.[3,11-13] Within a large clinical trial of the pre-
vention of mother-to-child transmission of HIV, we took
advantage of the fact that we had laboratories that were
certified by the National Institutes of Health performing
laboratory assessments with a high degree of oversight
and quality control. All laboratories were subject to rigor-
ous monitoring, including receipt of proficiency panels.
Thus, we were in an excellent position to provide labora-
tory data from both pregnant women and their newborn
offspring within a high quality laboratory environment in
four African cities. These data were collected to assess the
safety of the antibiotic intervention of the parent clinical
trial and the status of the patient vis-à-vis HIV infection or
risk. We describe hematological and biochemical meas-
ures and trends over time in a large cohort of pregnant
African women and infants with and without human
immunodeficiency virus type 1 (HIV) infection. Given the
magnitude of the current efforts to identify and treat HIV
disease in Africa, we believe that data from our large sam-
ple will prove helpful to service providers seeking to inter-
pret data from their own pregnant clinical subjects and
their infants.
Patients and Methods
The HIV Prevention Trials Network Protocol 024 Trial
The HIV Prevention Trials Network Protocol 024
(HPTN024) study was a Phase III randomized, double
blind, placebo-controlled clinical trial of antibiotics to
reduce chorioamnionitis-associated mother-to-child
transmission of HIV. The trial was conducted in four Afri-
can sites: Blantyre, Malawi, Lilongwe, Malawi; Dar-es-
Salaam, Tanzania; and Lusaka, Zambia. Prior to initiation
of the trial, approval was received from institutional
review boards or ethics committees at all participating
sites and universities. The findings of the HPTN024 trial
itself have been published showing that an antepartum
and peripartum antibiotic regimen did not reduce the risk
of MTCT of HIV-1 in African women with high prevalence
rates of bacterial vaginosis and subclinical chorioamnio-
nitis.[14] HIV-infected and HIV-uninfected women were
enrolled at 20–24 weeks gestation from antenatal clinics
from July 2001 to February 2003. By trial design, in three
of the four sites, there were five pregnant HIV-infected
women enrolled in the study for each pregnant HIV-unin-
fected woman. The principal exclusion criteria were
related to serious illness that would prevent the woman
from participating in a research study. Otherwise, subjects
were highly representative of the public sector clinics from
which they were recruited. All laboratory data indicated
for the parent protocol were obtained on each subject,
except that viral loads were not obtained if the subject was
HIV-uninfected.
Enrolled women were randomized to receive either met-
ronidazole 250 mg and erythromycin 250 mg every 8
hours for 7 days at 20–24 weeks, followed by metronida-
zole 250 mg and ampicillin 500 mg every 4 hours with
onset of premature rupture of membranes or labor, or
identically appearing placebos. Follow-up study visits
occurred at 28 weeks and 36 weeks gestation. Infant study
visits were conducted at birth and at 4–6 weeks of age. All
women received a conventional iron-containing vitamin/
mineral preparation designed for pregnant women (Tish-
con Corporation, Baltimore, MD) daily from enrolment
and until delivery. The supplement included: 30 mg iron,
400 mcg folic acid, 5000 IU vitamin A, 400 IU vitamin D,
30 IU vitamin E, 50 mg vitamin C, 2 mg vitamin B1, 3 mg
vitamin B2, 3 mg vitamin B6, 5 mcg vitamin B12, 20 mg
niacin, 250 mg calcium, 150 mcg iodine, 100 mg magne-
sium, and 15 mg zinc.
HIV-infected women were offered single dose nevirapine
(NVP) prophylaxis at delivery for prevention of mother-
to-child transmission of HIV. Infants of HIV-infected
women received NVP within 72 hours of birth. No other
antiretroviral drugs were used by mothers and infants in
the trial, as these drugs were unavailable in the study set-
tings at the time.BMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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All seroconverters had their baseline stored specimens
sampled by PCR so that persons who were acutely infected
at baseline could be excluded. Hence, we are certain that
our seronegative women were not acutely infected. Fur-
thermore, these baseline data were collected within a
month of enrolment, and often on the same day as enrol-
ment.
Since the clinicians were blinded to the randomized treat-
ment assignment, women were treated for all infections
per the local treatment guidelines. The receipt of non-
study antibiotics and all other medications received by the
women was recorded using open-ended questions in the
concomitant medications log form (data not presented).
We used structured questionnaires to collect information
on maternal demographics as well as medical, obstetric
and sexual histories. We estimated infant gestational age
through the neuromuscular and physical maturity indices
of the new Ballard examination. Trained nurses assessed
birth weights.
For infants born to the study women, only the first live
born infant was included in this analysis. If twins were
born, only the firstborn twin was included (since labora-
tory outcomes for twins are likely to be correlated).
Women could not be enrolled for subsequent pregnancies
if they had already enrolled previously.
Laboratory Procedures
Venous blood was collected from pregnant women at
both the 20- to 24-week visit and the 36-week visit. Blood
for complete blood counts (CBCs) was collected in ethyl-
enediaminetetraacetic acid (EDTA) vacutainers and ana-
lyzed at local laboratories on Coulter machines. Blood for
alanine aminotransferase (ALT) assays was stored in
EDTA vacutainers. Infant blood was collected by heel
stick. CBCs and lymphocyte subsets (counts and percent-
ages) were determined at both visits using HPTN Central
Lab-approved site-specific procedures. Analyses for CD4+
and CD8+ T lymphocyte cell counts were done using FAC-
SCount™ flow cytometer in three sites (Dar-es-Salaam,
Lilongwe and Lusaka) while one site (Blantyre) used FAC-
Scan™ flow cytometer. All analyses were done according to
the manufacturer's procedures. For infants, CBCs were
obtained at both the birth visit and the 4–6-week visit. At
the 4–6-week visit, ALT assays were performed with chem-
istry analyzers according to manufacturer's protocols.
Blood samples from the pregnant women were screened
for HIV at local laboratories using two different enzyme
linked immunosorbent assays (ELISA), and confirmed
with Western blot assays. The HIV infection status of
infants at birth and 4–6 weeks of age was determined by
analyzing dried blood spots, using a polymerase chain
reaction (PCR)-based HIV RNA assay. Results from ELISA
assays (for women) and HIV RNA assays (for infants) were
confirmed centrally.
Infants were categorized as HIV-uninfected at birth if they
had a negative HIV RNA assay at birth, or if they were
missing an HIV RNA result from the birth visit, but had a
negative HIV RNA test at 4–6 weeks of age. Infants who
had a negative HIV RNA test at birth, but a positive HIV
RNA test at 4–6 weeks were categorized as HIV-uninfected
at birth, and as HIV-infected at 4–6 weeks of age.
The HPTN Central Laboratory at Johns Hopkins Univer-
sity reviewed and certified all local laboratories before the
initiation of the trial. The Central Laboratory verified viro-
logical, serological, hematological, immunological, and
biochemical tests based on proficiency panels provided by
the College of American Pathology (CAP) and United
Kingdom (U.K.) National External Quality Assessment
Service (UKNEQAS) on a periodic basis throughout the
trial.
Statistical Analysis
We summarized all laboratory values by their means, 95%
confidence intervals (2.5th and 97.5th percentiles), and cal-
culated their associated standard deviations for HIV-
infected and HIV-uninfected women and infants sepa-
rately. Two-sample comparisons were done by hypothesis
testing on continuous and categorical outcomes using the
Student's t-test and the Chi-square test (or the Fisher's
exact test, when indicated), respectively. Comparison on
changes in laboratory measures between visits (20–24
weeks and 36 weeks) was done by hypothesis testing
using paired sample t-tests. Similar analyses were also per-
formed for infants (birth visit and 4–6 week visit).
Results
Size and Characteristics of the Study Population
We enrolled 2,659 eligible pregnant women into
HPTN024. Of these 2,659 women, 2,292 (86%) were
HIV-infected and 367 (14%) were uninfected (Figure 1).
There were 2,382 live born infants (2,052 born to HIV-
infected women and 331 born to uninfected women). The
mean gestational age at birth (n = 2382) was 38.4 (± 0.06)
weeks using the new Ballard score. The mean birth weight
in the study was 2,957 (± 11.8) grams. Infants born to
HIV-infected mothers had a 37-gram lower mean birth
weight compared to infants born to HIV-uninfected
mothers (2980 grams ± 505; 95% ci: 2957–3005 vs. 3079
grams ± 515; 95% ci: 3023–3135; respectively; p = 0.002
by Student's t test). The mean head circumference was
34.6 (± 0.05) cm. The mean Apgar score at 1 minute was
8.2 (± 0.03) and was 9.6 (± 0.03) at 5 minutes.BMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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Of the 2,052 infants born to HIV-infected women, receipt
of NVP prophylaxis was as follows: both mother and
infant received NVP (1,817), mother received NVP but
infant did not (143), mother did not receive NVP but
infant did (52), and neither mother nor infant received
NVP (40 pairs). None of the infants born to HIV-unin-
fected mothers was exposed to NVP.
HIV-infected women were, on average, two years older
than HIV-uninfected women (p < 0.001); education levels
were comparable (Table 1). Infants of HIV-infected
women had lower birth weights than those born to HIV-
uninfected women: 2,936 (± 12.9) grams vs. 3,090 (±
28.2) grams, respectively (p < 0.0001). Mean head cir-
cumference was also lower among infants of HIV-infected
women compared to the mean head circumferences of
those born to HIV-uninfected women (Table 1).
Laboratory Measures in Pregnant Women
Tables 2 and 3 compare the hematological values for HIV-
infected versus HIV-uninfected pregnant women at 20–24
weeks (Table 2) and at 36 weeks (Table 3). At both 20–24
weeks and 36 weeks, HIV-infected pregnant women had
lower red blood cell (RBC) counts, hemoglobin, hemat-
ocrit, and WBC counts than HIV-uninfected women.
Platelet counts and the monocyte differential counts were
higher in HIV-infected women than in HIV-uninfected
women at both time points. The CD4+ T lymphocyte cell
counts (CD4+ cell count) were lower in HIV-infected
women compared to HIV-uninfected women. From the
paired samples' t-test (comparing the changes in CD4+
cell count at 20–24 weeks vs. 36 weeks), the CD4+ cell
counts increased during pregnancy among the HIV-
infected women (p = 0.0002), while there was no signifi-
Patient recruitment and retention for the HIV Prevention  Trials Network 024 randomized clinical trial protocol in  Malawi, Tanzania, and Zambia Figure 1
Patient recruitment and retention for the HIV Pre-
vention Trials Network 024 randomized clinical trial 
protocol in Malawi, Tanzania, and Zambia.
Table 1: Selected characteristics of pregnant women and their infants according to maternal HIV infection status
Pregnant women in antenatal care HIV-infected women HIV-uninfected women P value
N = 2292 n = 367
Mean age in years (± SD) 25.2 (0.1) 23.2 (0.3) < 0.0001
Able to read % 77.3% 79.8% 0.3
Homemakers % 77.7% 86.6% 0.0002
Mean years of education (± SD) 6.6 (0.1) 6.8 (0.2) 0.2
Married or living with partner % 91.5% 96.7% < 0.0005
Spouse with formal employment % 54.6% 56.6% 0.8
Spouse's years of education (± SD) 9.2 (0.1) 9.3 (0.2) 0.5
Lives in own house % 25.7% 31.3% 0.0015
Electricity in the house % 40.5% 33.8% 0.02
Running water % 42.1% 33.8% 0.003
Infants born to enrolled women* Mother HIV-infected Mother HIV-uninfected P value
N = 2052 N = 331
Mean birth weight in grams (± SD) 2936.1 (12.9) 3090.4 (28.2) < 0.0001
Mean Apgar score at 5 min (± SD) 9.6 (< 0.01) 9.6 (0.1) 0.4
Mean gestational age in weeks (± SD) 38.4 (0.1) 38.4 (0.1) 0.9
Mean head circumference (± SD) 34.5 (0.1) 34.9 (0.1) 0.02
Male sex % 50.5% 48.0% 0.4
* Live born infants; if twin, then first born onlyBMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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cant change in this measure among the HIV-uninfected
women. The mean of the paired differences of CD4+ cell
counts among HIV-infected women was +14.8 cells/μL
from the 20–24-week visit compared to the 36-week ante-
natal visit.
About one-quarter of the women who had been seen at
the 20–24-week visit were not seen at the 36-week visit.
The mean maternal age for women who were seen only at
20–24 weeks was 24.5 ± 5.0 years, while women seen
both at gestational age 20–24 weeks as well as at 36 weeks
were six months older, on average (mean age of 25.1 ± 4.8
years; p = 0.004). Log viral load of women who were seen
only at 20–24 weeks was 4.39 ± 0.78 log10 copies/mL
while women seen both at gestational age 20–24 weeks as
well as at 36 weeks had a 0.15 log10 copies/mL lower
mean viral load of 4.24 ± 0.82 log10 copies/mL (p =
0.0002). We highlight the relevance of this observation,
related to the CD4+ cell count changes in the discussion.
We found the differences between HIV-infected and unin-
fected pregnant women to persist, for the most part,
throughout the range of CD4+ cell counts (Tables 4, 5, 6
and 7). For example, even women with HIV infection and
CD4+ cell counts >500/μL had lower hemoglobins and
higher platelet counts than did HIV-uninfected women
(Table 7). As one would expect, hematogical parameters
were more aberrant in women with lowest CD4+ cell
counts (Table 4).
Tables 8 and 9 give the paired sample t-tests for the labo-
ratory values between the two time points in pregnancy,
Table 2: Laboratory values among HIV-infected and HIV-uninfected pregnant women at 20–24 weeks gestation
Laboratory Parameter HIV-infected HIV-uninfected p value*
n Mean ± SD 95% CI n Mean ± SD 95% CI
Lower Upper Lower Upper
Red blood cell count 106/μL2 2 6 6 3.6 ± 0.5 2.56 4.65 367 3.8 ± 0.6 2.65 4.92 < 0.0001
Hemoglobin g/dl 2262 10.1 ± 1.4 7.1 12.7 367 11.0 ± 1.3 8.2 13.2 < 0.0001
Hematocrit % 2265 29.9 ± 4.2 21.4 37.7 367 32.3 ± 4.6 23.8 39.4 < 0.0001
Platelets 103/μL2 2 6 7 231.6 ± 79.9 102 410 367 204.3 ± 64.9 97 350 < 0.0001
White blood cell count 103/μL2 2 6 6 6.1 ± 2.0 2.9 10.3 366 6.9 ± 1.9 3.3 11.1 < 0.0001
Lymphocytes % 2197 31.0 ± 9.9 16.4 58.1 358 31.5 ± 8.7 19 57 0.4
Monocytes % 2197 8.1 ± 5.0 1.9 20.9 358 6.8 ± 4.4 1.9 17 < 0.0001
Granulocytes % 2198 60.7 ± 12.5 22.8 78.6 358 61.7 ± 10.8 28.6 77.5 0.1
CD4+ T lymphocyte count cells/μL2 0 7 2 374.4 ± 214.6 64 899 246 809.6 ± 257.9 344 1366 < 0.0001
CD8+ T lymphocyte count cells/μL2 0 7 2 771.1 ± 357.6 276 1674 246 513.5 ± 196.8 262 1002 < 0.0001
CD4+ T lymphocyte % 287 23.3 ± 10.7 54 6 5 5 47.6 ± 8.4 33 65 < 0.0001
CD8+ T lymphocyte % 287 55.4 ± 15.3 26 83 55 31.7 ± 8.4 18 50 < 0.0001
Total T lymphocytes as a % of all lymphocytes 235 74.5 ± 14.4 21 94 47 75.6 ± 8.3 60 93 0.6
*P values by Student's t test comparing laboratory values of HIV-infected and HIV-uninfected pregnant women at 20–24 weeks gestation.
Table 3: Laboratory values among HIV-infected and HIV-uninfected pregnant women at 36 weeks gestation
Laboratory Parameter HIV-infected HIV-uninfected p value
n Mean ± SD 95% CI n Mean ± SD 95% CI
Lower Upper Lower Upper
Red blood cell count 106/μL1 6 4 3 3.8 ± 0.6 2.78 4.94 280 3.9 ± 0.7 2.865 5.34 < 0.0001
Hemoglobin g/dl 1642 10.7 ± 1.4 7.9 13.2 280 11.3 ± 1.3 9 13.95 < 0.0001
Hematocrit % 1643 31.7 ± 4.3 23.3 39.5 280 33.3 ± 4.2 25.9 41.85 < 0.0001
Platelets 103/μL1 6 4 2 209.8 ± 79.1 88 402 280 182.9 ± 64.8 86.5 344.5 < 0.0001
White blood cell count 103/μL1 6 3 9 6.1 ± 2.0 3.1 10.2 280 6.7 ± 2.1 3.8 11.2 < 0.0001
Lymphocytes % 1633 31.4 ± 8.7 16.7 50.5 274 31.8 ± 8.4 18.1 53.6 0.5
Monocytes % 1633 8.4 ± 5.1 2.1 21.9 274 7.5 ± 5.3 1.1 23.1 0.01
Granulocytes % 1632 60.1 ± 11.0 32.1 77.8 274 60.7 ± 10.8 32.6 76.5 0.4
CD4+ T lymphocyte count cells/μμL1 4 5 9 399.8 ± 222.7 65 901 166 786.0 ± 266.4 368 1325 < 0.0001
CD8+ T lymphocyte count cells/μL1 4 5 9 776.2 ± 336.3 293 1618 166 506.8 ± 218.5 216 1106 < 0.0001
CD4+ T lymphocyte % 185 24.2 ± 10.4 44 3 4 9 45.0 ± 9.3 28 66 < 0.0001
CD8+ lymphocyte % 185 54.0 ± 12.5 32 79 49 31.1 ± 7.4 21 43 < 0.0001
Total T lymphocytes as a % of all lymphocytes 173 77.5 ± 9.7 57 92 43 74.1 ± 9.6 54 90 0.04
Note: Indicates t-test P values comparing laboratory values between HIV-infected and HIV-uninfected women at 36 weeks gestationBMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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among HIV-infected women and HIV-uninfected women,
respectively. In both groups, the RBC count, hemoglobin,
hematocrit and differential monocyte count increased
between the 20–24-week and the 36-week visits.
Laboratory Measures in Infants
We compared hematological measures of HIV-infected
versus HIV-uninfected infants at birth (Table 10) and at
4–6 weeks of age (Table 11). At birth, there were no signif-
icant differences in hemoglobin, hematocrit and white
blood cell (WBC) count between HIV-infected and HIV-
uninfected infants. At birth, HIV-infected infants had
lower platelet counts than HIV-uninfected infants. At the
4–6-week visit, HIV-infected infants had lower hemo-
globin and hematocrit values, lower platelet counts, and
higher ALT values than HIV-uninfected infants. Table 12
provides the difference between the laboratory values for
HIV-uninfected and HIV-infected infants at birth versus
4–6 weeks of age. Among the infants, hemoglobin, hema-
tocrit and WBC counts decreased in the first 4–6 weeks of
life, though platelet counts increased.
We categorized HIV-uninfected infants as to whether they
were born to HIV-infected mothers (termed HIV-exposed
infants) or to HIV-uninfected mothers (termed HIV-unex-
posed infants). HIV-exposed, but uninfected infants had
lower hemoglobin and hematocrit levels than HIV-unex-
posed infants both at birth (both p < 0.0001) and at 4–6
weeks (both p < 0.05; Table 13). Platelet counts did not
differ, while at the visit at 4–6 weeks of infant age, both
white blood cells and ALT were higher among exposed
infants (Table 13).
Table 4: Comparison of HIV-infected women with CD4+ cell counts <200/μL to HIV-uninfected women
HIV (+) CD4 < 200/μLH I V  ( - )
Laboratory measures Mean N P2.75 P97.5 Mean N P2.75 P97.5 P value
Study visit at 20–24 weeks gestation
Red blood cells 106/μL 3.4 448 2.4 4.6 3.8 367 2.9 4.9 < .0001
Hemoglobin g/dL 9.6 447 7.0 12.0 11.0 367 8.2 13.2 < .0001
Hematocrit % 28.5 447 21.3 35.9 32.3 367 23.8 39.4 < .0001
Platelets 103/μL 226.0 449 100 391 204.3 367 97 350 < .0001
White blood cells 103/μL 5.2 449 2.7 9 6.9 366 3.3 11.1 < .0001
Lymphocytes % 28.0 435 12.8 55.1 31.5 358 19 57 < .0001
Monocytes % 8.9 435 2.4 23.8 6.8 358 1.9 17 < .0001
Granulocytes % 63.0 436 24 81.8 61.7 358 28.6 77.5 0.1
CD4+ cells/μL 130 456 26 198 809.6 246 344 1366 < .0001
CD8+ cells/μL 661 456 192 1615 513.5 246 262 1002 < .0001
CD4 % 14.0 89 3 29 47.6 55 33 65 < .0001
CD8 % 59.7 89 15 88 31.7 55 18 50 < .0001
Total T-Lymphocytes as % of all lymphocytes 69.6 76 17 92 75.6 47 60 93 0.04
Study visit at 36 weeks gestation
Red blood cells 106/μL 3.7 279 2.6 4.9 3.9 280 2.9 5.3 < .0001
Hemoglobin g/dL 10.4 279 7.4 13.2 11.3 280 9.0 14.0 < .0001
Hematocrit % 30.8 279 22.6 39.0 33.3 280 25.9 41.9 < .0001
Platelets 103/μL 208.8 279 77 419 182.9 280 87 345 < .0001
White blood cells 103/μL 5.0 279 2.4 8.5 6.7 280 3.8 11.2 < .0001
Lymphocytes % 28.7 279 13.5 51.6 31.8 274 18.1 53.6 < .0001
Monocytes % 8.8 279 2.6 21.9 7.5 274 1.1 23.1 0.003
Granulocytes % 62.5 279 35.6 80.4 60.7 274 32.6 76.5 0.06
CD4+ cells/μL 131 280 19 196 786 166 368 1325 < .0001
CD8+ cells/μL 656 280 215 1524 507 166 216 1106 < .0001
CD4 % 13.8 49 3 29 45.0 49 28 66 < .0001
CD8 % 60.2 49 34 88 31.1 49 21 43 < .0001
Total T-Lymphocytes as % of all lymphocytes 74.9 47 50 93 74.1 43 54 90 0.7
Laboratory values for pregnant women at the 20–24-week gestational age visit and at the 36-week visit. Of the 2633 women with data at baseline, 
727 (27.6%) were missing week 36 data and 1906 (72.4%) had 36-week data. It is possible that week 36 women were slightly healthier than week 
20–24 women, since the 36 week women had a slightly higher CD4+ cell count and may have been more likely to be able to keep the 36-week 
appointment (see discussion).
Lower 95% confidence interval = P2.75 = 2.75%ile
Upper 95% confidence interval = P97.5 = 97.5%ileBMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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Among HIV-uninfected infants (by PCR at 6 weeks of
age), HIV-exposed infants had a 37-gram lower mean
birth weight compared to HIV-unexposed infants (2980 ±
505 grams; 95% ci: 2957–3005 vs. 3079 ± 515 grams;
95% ci: 3023–3135, respectively; p = 0.002).
Discussion and Conclusion
A four-site clinical trial in Malawi, Tanzania, and Zambia
enabled us to document hematological, biochemical, and
immunological measures in a large cohort of pregnant
African women with and without HIV infection, and in
their infants. The infants were either HIV-infected, HIV-
exposed but uninfected, or were uninfected and unex-
posed to HIV. HIV-infected pregnant women had lower
red blood cell counts, hemoglobins, hematocrits and
WBC counts than the HIV-uninfected cohort. However,
platelet and monocyte counts were higher in HIV-infected
women than in the HIV-uninfected women. Although val-
ues were similar at birth, HIV-infected infants had lower
hemoglobin, hematocrit, and platelet counts at 4–6 weeks
of age, but had higher ALT values, compared to HIV-unin-
fected infants. Among the HIV-uninfected infants, the
HIV-exposed babies had lower hemoglobins/hematocrits,
but had higher white blood cell counts and ALT levels
than did the HIV-unexposed infants at 4–6 weeks of age.
As one might expect, HIV-infected women were more
likely to be anemic (hemoglobin <12 g/dL) than HIV-
uninfected women.[1] One possible cause of anemia in
these women could be the effect of HIV infection on
hematopoiesis. The mean maternal hemoglobin levels in
both HIV-infected and HIV-uninfected women in this
Table 5: Comparison of HIV-infected women with CD4+ cell counts 200–349/μL to HIV-uninfected women
HIV (+) CD4 200–349/μLH I V  ( - )
Laboratory measures Mean N P2.75 P97.5 Mean N P2.75 P97.5 P value
Study visit at 20–24 weeks gestation
Red blood cells 106/μL 3.5 608 2.53 4.52 3.8 367 2.65 4.92 < .0001
Hemoglobin g/dL 10.0 607 6.7 12.2 11.0 367 8.2 13.2 < .0001
Hematocrit % 29.5 608 21 36.4 32.3 367 23.8 39.4 < .0001
Platelets 103/μL 231.9 608 101 413 204.3 367 97 350 < .0001
White blood cells 103/μL 5.7 608 2.6 9.1 6.9 366 3.3 11.1 < .0001
Lymphocytes % 30.4 597 16.4 58.1 31.5 358 19 57 0.0778
Monocytes % 8.4 597 2.1 21.4 6.8 358 1.9 17 < .0001
Granulocytes % 60.8 597 21.1 78.7 61.7 358 28.6 77.5 0.3
CD4 cells/μL 272.8 612 202 346 809.6 246 344 1366 < .0001
CD8 cells/μL 737.0 612 284 1589 513.5 246 262 1002 < .0001
CD4 % 22.7 92 12 37 47.6 55 33 65 < .0001
CD8 % 57.3 92 31 82 31.7 55 18 50 < .0001
Total T-Lymphocytes as % of all lymphocytes 76.4 75 48 98 75.6 47 60 93 0.7
Study visit at 36 weeks gestation
Red blood cells 106/μL 3.7 391 2.75 4.87 3.9 280 2.865 5.34 < .0001
Hemoglobin g/dL 10.5 391 7.9 13 11.3 280 9 13.95 < .0001
Hematocrit % 31.1 391 22.4 38.5 33.3 280 25.9 41.85 < .0001
Platelets 103/μL 201.6 391 88 356 182.9 280 86.5 344.5 0.0005
White blood cells 103/μL 5.6 391 3.3 8.9 6.7 280 3.8 11.2 < .0001
Lymphocytes % 30.8 387 16.2 50.7 31.8 274 18.1 53.6 0.1
Monocytes % 8.8 387 2.4 22.5 7.5 274 1.1 23.1 0.0020
Granulocytes % 60.2 387 30.4 78.5 60.7 274 32.6 76.5 0.6
CD4+ cells/μL 274.8 395 202 346 786.0 166 368 1325 < .0001
CD8+ cells/μL 757.2 395 313 1731 506.8 166 216 1106 < .0001
CD4 % 24.3 66 13 42 45.0 49 28 66 < .0001
CD8 % 54.1 66 32 73 31.1 49 21 43 < .0001
Total T-Lymphocytes as % of all lymphocytes 78.0 63 61 91 74.1 43 54 90 0.02
Laboratory values for pregnant women at the 20–24-week gestational age visit and at the 36-week visit. Of the 2633 women with data at baseline, 
727 (27.6%) were missing week 36 data and 1906 (72.4%) had 36-week data. It is possible that week 36 women were slightly healthier than week 
20–24 women, since the 36 week women had a slightly higher CD4+ cell count and may have been more likely to be able to keep the 36-week 
appointment (see discussion).
Lower 95% confidence interval = P2.75 = 2.75%ile
Upper 95% confidence interval = P97.5 = 97.5%ileBMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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study were lower than the values reported elsewhere for
African pregnant women (mean = 12.1 g/dL).[1] The lev-
els of hemoglobin in this study are similar to those
reported previously for pregnant Indian women (mean =
11.1 ± 1.6 g/dL).[15] Lower hemoglobin levels in this
study may be seen in individuals with malarial infection,
but no recruited women had suspected malaria and all
were recruited at urban sites with low prevalence rates of
malaria. A Nigerian study found that anemia was twice as
common in HIV-infected subjects who had malaria para-
sites, compared to non-parasitized controls.[16] In this
study, routine malaria blood smears were not done at the
time of laboratory testing. No women were on zidovudine
as potent antiretroviral therapy and zidovudine for
PMTCT were not in use at the time of the study. Women
were supplemented with iron during pregnancy, so the
true magnitude of anemia may be greater than what we
report from this clinical trial.
Mean WBC counts were within the ranges of those previ-
ously described.[1] The WBC count for normal male and
female adults is 4,500–11,000/μL (range is estimate of
95% confidence limits).[17] One study reported that
although changes in leukocyte counts during pregnancy
in African women were similar to those reported in Cau-
casian women, the total WBC counts were lower in the
African women.[5]
Although hematological parameters were comparable at
birth between HIV-infected infants and HIV-uninfected
infants, HIV-infected infants showed a greater decrease in
hemoglobin concentrations than HIV-uninfected infants
Table 6: Comparison of HIV-infected women with CD4+ cell counts 350–500/μL to HIV-uninfected women
HIV (+) CD4 350–500/μLH I V  ( - )
Laboratory measures Mean N P2.75 P97.5 Mean N P2.75 P97.5 P value
Study visit at 20–24 weeks gestation
Red blood cells 106/μL 3.6 488 2.7 4.6 3.8 367 2.7 4.9 < .0001
Hemoglobin g/dL 10.3 486 7.1 12.7 11.0 367 8.2 13.2 < .0001
Hematocrit % 30.2 488 21.6 37.4 32.3 367 23.8 39.4 < .0001
Platelets 103/μL 227.8 488 103 399 204.3 367 97 350 < .0001
White blood cells 103/μL 6.2 488 2.8 9.5 6.9 366 3.3 11.1 < .0001
Lymphocytes % 32.2 481 19.0 62.5 31.5 358 19.0 57.0 0.3
Monocytes % 7.7 481 1.7 17.7 6.8 358 1.9 17.0 0.004
Granulocytes % 59.9 481 21.4 75.5 61.7 358 28.6 77.5 0.03
CD4+ cells/μL 418 489 352 495 810 246 344 1366 < .0001
CD8+ cells/μL 788 489 349 1602 514 246 262 1002 < .0001
CD4 % 28.6 49 17 52 47.6 55 33 65 < .0001
CD8 % 51.7 49 22 77 31.7 55 18 50 < .0001
Total T-Lymphocytes as % of all lymphocytes 77.0 40 46 96.5 75.6 47 60 93 0.5
Study visit at 36 weeks gestation
Red blood cells 106/μL 3.8 356 2.8 4.9 3.9 280 2.9 5.3 0.002
Hemoglobin g/dL 10.7 356 8 13.5 11.3 280 9 14.0 < .0001
Hematocrit % 31.7 356 23.3 40 33.3 280 25.9 41.9 < .0001
Platelets 103/μL 214.0 356 86 448 182.9 280 87 345 < .0001
White blood cells 103/μL 6.1 356 3.3 9.9 6.7 280 3.8 11.2 < .0001
Lymphocytes % 31.6 356 19.3 53.4 31.8 274 18.1 53.6 0.8
Monocytes % 8.6 356 2.5 23.5 7.5 274 1.1 23.1 0.01
Granulocytes % 59.6 356 29.5 75.0 60.7 274 32.6 76.5 0.2
CD4+ cells/μL 418 359 353 495 786 166 368 1325 < .0001
CD8+ cells/μL 779 359 340 1515 507 166 216 1106 < .0001
CD4 % 28.2 36 12 50 45.0 49 28 66 < .0001
CD8 % 51.8 36 20 76 31.1 49 21 43 < .0001
Total T-Lymphocytes as % of all lymphocytes 78.4 34 57 92 74.1 43 54 90 0.05
Laboratory values for pregnant women at the 20–24-week gestational age visit and at the 36-week visit. Of the 2633 women with data at baseline, 
727 (27.6%) were missing week 36 data and 1906 (72.4%) had 36-week data. It is possible that week 36 women were slightly healthier than week 
20–24 women, since the 36 week women had a slightly higher CD4+ cell count and may have been more likely to be able to keep the 36-week 
appointment (see discussion).
Lower 95% confidence interval = P2.75 = 2.75%ile
Upper 95% confidence interval = P97.5 = 97.5%ileBMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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in the first 4–6 weeks of life. Similar findings have been
found in a large cohort of HIV-infected and uninfected
infants in Malawi.[8] In this study, hemoglobin levels
were lower among HIV-infected infants whose mothers
had received NVP prophylaxis, and higher among HIV-
uninfected infants who were not exposed to NVP prophy-
laxis. We were not able to assess whether the lower hemo-
globin levels seen in HIV-infected infants in HPTN024
were due to HIV infection or NVP exposure, since nearly
all HIV-infected women and their infants in this cohort
received NVP prophylaxis.
HIV-infected infants had higher ALT levels than HIV-unin-
fected infants at 4–6 weeks of age. Increased ALT levels in
infants may suggest acute liver inflammation, though ALT
values are variable in infants and may be linked to NVP
exposure.[8] Given near universal NVP prophylaxis in our
cohort, we were not able to determine whether the higher
ALT levels were related to HIV infection status per se, or
NVP exposure. The higher ALT level in the HIV-exposed
infants who were not infected, compared to HIV-unin-
fected and unexposed infants, may also have been due to
NVP exposure, but this will require further study. The
magnitude of the ALT rise was not substantial and the
highest ALT in an HIV-exposed (and NVP-exposed) infant
was only 63 IU/liter (Table 9).
The mean hemoglobin value for normal infants has been
reported as 18.5 g/dL in a neonate ages 1–3 days in stand-
ard hematological references (Table 14),[17] similar to
our study and a study in Malawi.[8] Perhaps the iron-con-
taining vitamin and mineral supplements in our mothers
Table 7: Comparison of HIV-infected women with CD4+ cell counts >500/μL to HIV-uninfected women
HIV (+) CD4 > 500/μLH I V  ( - )
Laboratory measures Mean N P2.75 P97.5 Mean N P2.75 P97.5 P value
Study visit at 20–24 weeks gestation
Red blood cells 106/μL 3.7 512 2.8 4.8 3.8 367 2.7 4.9 0.01
Hemoglobin g/dL 10.5 512 7.7 13 11.0 367 8.2 13.2 < .0001
Hematocrit % 30.9 512 21.5 38.5 32.3 367 23.8 39.4 < .0001
Platelets 103/μL 242.9 512 111 453 204.3 367 97 350 < .0001
White blood cells 103/μL 7.2 513 3.5 12.0 6.9 366 3.3 11.1 0.02
Lymphocytes % 33.7 506 20.1 60.1 31.5 358 19.0 57.0 0.0005
Monocytes % 7.7 506 1.2 21.2 6.8 358 1.9 17.0 0.008
Granulocytes % 58.2 506 21.5 73.4 61.7 358 28.6 77.5 < .0001
CD4+ cells/μL 670 515 504 1090 810 246 344 1366 < .0001
CD8+ cells/μL 893 515 364 1919 514 246 262 1002 < .0001
CD4 % 34.4 56 16 51 47.6 55 33 65 < .0001
CD8 % 48.1 56 28 71 31.7 55 18 50 < .0001
Total T-Lymphocytes as % of all lymphocytes 77.4 43 55 94 75.6 47 60 93 0.4
Study visit at 36 weeks gestation
Red blood cells 106/μL 3.9 422 2.9 5.0 3.9 280 2.9 5.3 0.3
Hemoglobin g/dl 11.0 422 8.4 13.2 11.3 280 9.0 14.0 0.003
Hematocrit % 32.7 422 23.6 40.0 33.3 280 25.9 41.9 0.06
Platelets 103/μL 212.2 422 104 382 183 280 87 345 < .0001
White blood cells 103/μL 7.1 421 4.3 11.0 6.7 280 3.8 11.2 0.01
Lymphocytes % 33.3 417 18.5 50.3 31.8 274 18.1 53.6 0.01
Monocytes % 7.9 417 1.9 19.1 7.5 274 1.1 23.1 0.4
Granulocytes % 58.7 417 33.8 74.2 60.7 274 32.6 76.5 0.02
CD4+ cells/μL 677 425 507 1155 786 166 368 1325 < .0001
CD8+ cells/μL 870 425 395 1639 507 166 216 1106 < .0001
CD4 % 35.2 33 16 53 45.0 49 28 66 < .0001
CD8 % 47.1 33 29 68 31.1 49 21 43 < .0001
Total T-Lymphocytes as % of all lymphocytes 79.3 28 60 91 74.1 43 54 90 0.02
Laboratory values for pregnant women at the 20–24-week gestational age visit and at the 36-week visit. Of the 2633 women with data at baseline, 
727 (27.6%) were missing week 36 data and 1906 (72.4%) had 36-week data. It is possible that week 36 women were slightly healthier than week 
20–24 women, since the 36 week women had a slightly higher CD4+ cell count and may have been more likely to be able to keep the 36-week 
appointment (see discussion).
Lower 95% confidence interval = P2.75 = 2.75%ile
Upper 95% confidence interval = P97.5 = 97.5%ileBMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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improved infants' hemoglobin levels, as noted in a Tanza-
nian study.[11] These values are 2 g/dL higher than those
reported in two other African studies done in Malawi and
Nigeria that suggested that the hemoglobin values at birth
were lower in African than Caucasian children.[2,6] The
hemoglobin levels in this study were also higher than
those found in a study of Italian neonates in which the
mean hemoglobin level in term, appropriate-for-age
neonates was only 14.4 (± 4.4) g/dL.[18] Two studies in
India and one in Turkey also reported lower hemoglobin
levels than found in studying our African new-
borns.[15,19,20] Newborn hemoglobin and hematocrit
levels may be influenced by many factors, including the
mode of delivery.[21] For example, if a midwife holds a
baby a bit lower than the level of the mother's pelvis and
the not-yet-delivered placenta immediately after birth and
before the cord is clamped, the baby's hemoglobin can be
raised. WBC counts in infants in HPTN024 are within the
normal ranges of standard references for largely Caucasian
infants whose mean WBC value for normal infants at birth
is 18.1/μL (Table 14).[17]
Hematological and biochemical measurements can also
be useful for clinical monitoring of HIV-infected individ-
uals when viral load testing and CD4+ cell count monitor-
ing are not readily available.[22] Whether they could be
useful surrogates for pregnant women or young children
is not known. There are findings that will require specific
study, including the higher platelet counts noted in our
HIV-infected mothers, but lower platelet counts in the
HIV-infected infants, for which we do not have a ready
explanation.[2,9,23-26]
Table 8: Comparison of laboratory values at 20–24 weeks vs. 36 weeks gestation among HIV-infected women
Laboratory Parameter Number of Pairs Mean (*) of the paired differences 95% CI p value*
Lower Upper
Red blood cell count 106/μL 1626 0.17 0.23 < 0.0001
Hemoglobin g/dl 1623 0.5 0.4 0.6 < 0.0001
Hematocrit % 1626 1.5 1.3 1.7 < 0.0001
Platelets 103/μL 1625 -23.9 -27.5 -20.4 < 0.0001
White blood cell count 103/μL 1623 -0.1 -0.2 0.1 0.3
Lymphocytes % 1570 0.5 0.0 1.0 0.1
Monocytes % 1570 0.5 0.2 0.9 0.002
Granulocytes % 1569 -0.8 -1.6 -0.1 0.02
CD4+ T lymphocyte count cells/μL 1343 14.8 7.1 22.5 0.0002
CD8+ T lymphocyte count cells/μL 1343 8.5 -6.6 23.5 0.3
CD4+ T lymphocyte % 107 -2.3 -3.7 -0.8 0.003
CD8+ T lymphocyte % 107 -2.5 -4.6 -0.4 0.02
Total T lymphocytes as a % of all lymphocytes 74 -1.3 -3.7 1.1 0.3
* For each pair, the 20–24 week laboratory value is subtracted from the 36 week value. Hence, a negative value indicates a decrease over time in 
the laboratory parameter.
Table 9: Comparison of laboratory values at 20–24 weeks vs. 36 weeks gestation among HIV-uninfected women
Laboratory Parameter Number of Pairs Mean (*) of the paired differences 95% CI p value*
Lower Upper
Red blood cells count 106/μL 280 0.2 0.1 0.3 < 0.0001
Hemoglobin g/dl 280 0.2 0.1 0.4 0.01
Hematocrit % 280 0.7 0.1 1.3 0.01
Platelets 103/μL 280 -17.6 -25.1 -10.0 < 0.0001
White blood cell count 103/μL 279 -0.2 -0.4 0.1 0.2
Lymphocytes % 266 0.1 -1.1 1.2 0.9
Monocytes % 266 0.9 0.1 1.7 0.02
Granulocytes % 266 -0.9 -2.5 0.6 0.2
CD4+ T lymphocyte count cells/μL 134 -24.2 -71.9 23.6 0.3
CD8+ T lymphocyte count cells/μL 134 -12.5 -52.5 27.5 0.5
CD4+ T lymphocyte % 25 -2.5 -6.2 1.3 0.2
CD8+ T lymphocyte % 25 -1.2 -3.6 1.3 0.3
Total T lymphocytes as a % of all lymphocytes 19 1.1 -3.1 5.2 0.6
(*) For each pair, the 20–24 week laboratory value is subtracted from the 36 week value. Hence, a negative value indicates a decrease over time in 
the laboratory parameter.BMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
Page 11 of 14
(page number not for citation purposes)
Table 10: Laboratory values among HIV-infected and HIV-uninfected infants (both exposed and unexposed to HIV) at birth
Laboratory 
Parameter
HIV-uninfected Infants HIV-infected Infants P value
n Mean ± Standard 
Deviation
95% CI n Mean ± Standard 
Deviation
95% CI
Lower Upper Lower Upper
Hemoglobin g/dl 1900 18.5 ± 4.3 10.1 28.2 149 18.0 ± 3.7 10.4 24.6 0.1
Hematocrit % 1897 54.8 ± 12.1 29.7 80.2 149 53.5 ± 10.8 29.8 72.3 0.2
Platelets 103/μL1 8 9 3 240.8 ± 102.7 76 458 147 207.0 ± 97.3 37 419 < 0.0001
White blood cell count 
103/μL
1865 15.5 ± 6.2 5.8 30.6 145 15.4 ± 10.5 3.4 39.7 0.8
Table 11: Laboratory values among HIV-infected and HIV-uninfected infants at 4–6 weeks of age
Laboratory 
Parameter
HIV-uninfected Infants HIV-infected Infants P value
n Mean ± Standard 
Deviation
95% CI n Mean ± Standard 
Deviation
95% CI
Lower Upper Lower Upper
Hemoglobin g/dl 1710 11.6 ± 2.6 7.7 18 269 11.2 ± 2.8 6.6 18.6 < 0.007
Hematocrit % 1710 34.0 ± 7.3 22.4 51.5 269 32.9 ± 8.5 18 55.2 < 0.02
Platelets 103/μL1 7 0 4 371.8 ± 156.3 90 697 269 306.5 ± 150.7 55 626 < 0.0001
White blood cell Count 
103/μL
1694 10.7 ± 4.2 52 0 . 9 2 6 8 11.6 ± 5.3 4.5 25.2 < 0.002
*ALT (SGPT) IU/L 1552 22.2 ± 24.1 56 2 2 7 2 30.8 ± 33.9 5 133 < 0.001
*ALT (SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase)
Table 12: Comparison of laboratory values at birth vs. 4–6 weeks of age among HIV-infected and HIV-uninfected infants
Laboratory 
Parameter
HIV-infected Infants HIV-uninfected Infants p value
Number of 
Pairs
Mean (*) of the 
paired 
differences
95% CI Number of 
Pairs
Mean (*) of the 
paired 
differences
95% CI
Lower Upper Lower Upper
Hemoglobin g/dl 124 -7.1 -7.8 -6.4 1301 -7.0 -7.2 -6.8 < 0.0001
Hematocrit % 124 -21.0 -23.0 -19.0 1298 -20.9 -21.6 -20.3 < 0.0001
Platelets 103/μL 122 89.2 64.0 114.5 1292 125.1 115.9 134.3 < 0.0001
White blood cell 
count 103/μL
119 -2.0 -3.4 0.5 1263 -4.8 -5.2 -4.5 0.009
(*) For each pair, the birth laboratory value is subtracted from the 4–6 week value. Hence a negative value indicates a decrease over time in the 
laboratory parameter.BMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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Red cell and white cell indices have been reported to be
affected by age, sex, diet, malnutrition, co-infection, and
medication intake.[1-4,27] A limitation of this study is
that these factors were not fully analyzed as potential con-
founders or interaction factors. We also present laboratory
values for women before and after receiving micronutrient
supplements, but are not certain that the differences at the
36-week visit are due to this supplementation as they were
received by all women and because women seen at the 36-
week visit may have been healthier than those missing
this visit (by virtue of the slightly higher mean CD4+ cell
count noted in the subset of women who came from their
36-week visit). Because this was a multi-center study in
three countries with a large sample size, one may be
tempted to assume that our results are generalizable for
pregnant African women and their infants receiving NVP
prophylaxis. However, our studies were in four urban
centers where antenatal clients received good primary care
and malaria was not contributing substantially to adverse
outcomes. In addition, the effects of overall improved
nutritional supplementation and upgraded antenatal care
may have improved birth outcomes. For example, the
comparable gestational ages of HIV-infected and HIV-
uninfected infants in our study might not have been
expected given the preponderance of preterm birth among
HIV-infected infants reported in the literature.[28] (Pre-
term birth and HIV infection may be associated with
reduced transplacental transfer of HIV-specific acquired
maternal immunity to babies who are born early.)
Availability of hematologic and biochemical data in sub-
Saharan pregnant women and their children with and
Table 14: Normal blood values in neonates, reference value data largely derived from North American Caucasians.
Red Blood Cell Values in Neonates: Mean and Lower Limit of Normal (-2 SD)
Hemoglobin (g/dL) Hematocrit (%) Red Cell Count (106/μL)
Age Mean -2 SD Mean -2 SD Mean -2 SD
Birth (cord blood) 16.5 13.5 51 42 4.7 3.9
1 to 3 days (capillary) 18.5 14.5 56 45 5.3 4.0
1 week 17.5 13.5 54 42 5.1 3.9
1 month 14.0 10.0 43 31 4.2 3.0
2 months 11.5 9.0 35 28 3.8 2.7
Mean and Range of Leukocyte Count and Differential Count Values in Neonates
Neonatal age in hours (hr) Total Leukocytes (103/μL) Neutrophils (103/μL) Lymphocytes (103/μL)
Mean Range Mean Range % Mean Range %
Birth 18.1 9.0 – 30.0 11.0 6.0 – 26.0 61 5.5 2.0 – 11.0 31
12 hr 22.8 13.0 – 38.0 15.5 6.0 – 28.0 68 5.5 2.0 – 11.0 24
24 hr 18.9 9.4 – 34.0 11.5 5.0 – 21.0 61 5.8 2.0 – 11.5 31
1 month 10.8 5.0 – 19.5 3.8 1.0 – 9.0 35 6.0 2.5 – 16.5 56
from Geaghan SM. Appendix B, Normal blood values: Selected health-associated values for neonatal, pediatric, and adult populations. Greer JP, 
Foerster J, Lukens JN., et al, eds. Wintrobe's Clinical Hematology (12th Ed.). Philadelphia: Lippincott Williams & Wilkins, 2009: 2584–6.
Table 13: Laboratory values for all infants who were HIV-uninfected at birth (negative by PCR at 6 weeks of age), by HIV exposure 
status at the first birth visit. 
Laboratory measures HIV-unexposed infant HIV-exposed infant p-value
N Mean 95% CI N Mean 95% CI
Lower Upper Lower Upper
Values at first research assessment after birth
Hemoglobin g/dL 275 19.4 10.6 28.8 1625 18.3 9.9 27.9 < .0001
Hematocrit % 275 58.0 33.0 85.8 1622 54.2 29.4 79.4 < .0001
Platelets 103/μL2 7 4 247.5 78.0 450.0 1619 239.7 75.0 458.0 0.2
White blood cells 103/μL2 7 2 15.9 6.5 33.0 1593 15.5 5.7 30.5 0.3
Values at research assessment at age 4–6 weeks of age
Hemoglobin g/dL 278 11.9 8.1 18.9 1432 11.6 7.6 17.9 0.02
Hematocrit % 278 34.8 22.7 53.4 1432 33.8 22.3 51 0.04
Platelets 103/μL2 7 7 383.4 104 704 1427 369.5 89 697 0.2
White blood cells 103/μL2 7 6 10.1 5.1 17.4 1418 10.9 5.0 21.3 0.006
*ALT (SGPT) IU/liter 123 16.4 53 8 1 4 2 9 22.7 56 3 0 . 0 0 5
* ALT (SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase)
HIV-exposed means that these infants were born to HIV-infected mothers, while HIV-unexposed infants were born to HIV-uninfected mothers. 
Alanine aminotransferase (serum glutamic pyruvic transaminase) was not performed at the birth visit.BMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
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without HIV infection can assist in clinical program devel-
opment, clinical research design and planning, training of
both health care providers, and community education.
Our large study of poor pregnant women who received
vitamin and nutrient supplementation and their offspring
in urban Africa provides new normative data that will be
useful comparison values for clinicians managing similar
patients with and without HIV.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KM, SHV, and RLG conceptualized the manuscript,
designed the analyses, and drafted the manuscript. YQC
and AM participated in the design of analyses, crafted the
tables from the dataset, and performed the statistical anal-
yses. JSR and MV oversaw the parent clinical trial and pro-
vided writing and editing input to the manuscript drafts.
KM, WU, and NC collected the data and helped conceptu-
alize the analysis. All authors read and approved the final
manuscript. Each author has participated sufficiently in
the work to take public responsibility for appropriate por-
tions of the content.
Acknowledgements
The authors thank the participants in the HPTN 024 study and the following 
members of the Protocol Team: Protocol Co-Chairs: Taha E. Taha, MD, 
PhD (Johns Hopkins University Bloomberg School of Public Health); Robert 
Goldenberg, MD (University of Alabama at Birmingham); In-Country Co-
Chairs/Investigators of Record: Newton Kumwenda, PhD, George Kafula-
fula, MBBS, FCOG (Blantyre, Malawi); Francis Martinson, MD, PhD 
(Lilongwe, Malawi); Gernard Msamanga, MD, ScD (Dar es Salaam, Tanza-
nia); Moses Sinkala, MD, MPH, Jeffrey Stringer, MD (Lusaka, Zambia); US 
Co-Chairs: Irving Hoffman, PA, MPH (University of North Carolina, Chapel 
Hill); Wafaie Fawzi, MD, DrPH (Harvard School of Public Health); In-Coun-
try Investigators, Consultants and Key Site Personnel: Robin Broadhead, 
MBBS, FRCP, George Liomba, MBBS, FRCPath, Johnstone Kumwenda, 
MBChB, MRCP, Tsedal Mebrahtu, ScM, Pauline Katunda, MHS, Maysoon 
Dahab, MHS (Blantyre, Malawi); Peter Kazembe, MBChB, David Chilongozi 
CO, MPH, Charles Chasela CO, MPH, George Joaki, MD, Willard 
Dzinyemba, Sam Kamanga (Lilongwe, Malawi); Elgius Lyamuya, MD, PhD, 
Charles Kilewo, MD, MMed, Karim Manji, MD, MMed, Sylvia Kaaya, MD, 
MS, Said Aboud, MD, MMed, Muhsin Sheriff MD, MPH, Elmar Saathoff, PhD, 
Priya Satow, MPH, Illuminata Ballonzi, SRN, Gretchen Antelman, ScD, 
Edgar Basheka, BPharm (Dar-es-Salaam, Tanzania); Victor Mudenda, MD, 
Christine Kaseba, MD, Maureen Njobvu, MD, Makungu Kabaso, MD, Muz-
ala Kapina, MD, Anthony Yeta, MD, Seraphine Kaminsa, MD, MPH, Con-
stantine Malama, MD, Dara Potter, MBA, Maclean Ukwimi, RN, Alison 
Taylor, BSc, Patrick Chipaila, MSc, Bernice Mwale, BPharm (Lusaka, Zam-
bia); U.S. Investigators, Consultants and Key Site Personnel: Priya Joshi, BS, 
Ada Cachafeiro, BS, Shermalyn Greene, PhD, Marker Turner, BS, Melissa 
Kerkau, BS, Paul Alabanza, BS, Amy James, BS, Som Siharath, BS, Tiffany 
Tribull, MS (UNC-CH); Saidi Kapiga, MD, ScD, George Seage, PhD (HSPH); 
Sten H. Vermund, MD, PhD, William Andrews, PhD, MD, Deedee Lyon, BS, 
MT(ASCP) (UAB); NIAID Medical Officer: Samuel Adeniyi-Jones, MD; 
NICHD Medical Officer: Jennifer S. Read, MD, MS, MPH, DTM&H; Proto-
col Pharmacologist: Scharla Estep, RPh, MS; Protocol Statisticians: Elizabeth 
R. Brown, ScD, Thomas R. Fleming, PhD, Anthony Mwatha, MS, Lei Wang, 
PhD, Ying Q. Chen, PhD; Protocol Virologist: Susan Fiscus, PhD; Protocol 
Operations Coordinator: Lynda Emel, PhD; Data Coordinators: Debra J. 
Lands, Ed.M, Ceceilia J. Dominique; Systems Analyst Programmers: Alice H. 
Fisher, BA, Martha Doyle; Protocol Specialist: Megan Valentine, PA-C, MS. 
Meredith Bortz contributed editorial expertise.
Sources of Support:
This study was supported by the HIV Network for Prevention Trials 
(HIVNET) and sponsored by the U.S. National Institute of Allergy and Infec-
tious Diseases (NIAID), National Institutes of Health, Department of 
Health and Human Services, through contract N01-AI-035173 with Family 
Health International; contract N01-AI-045200 with Fred Hutchinson Can-
cer Research Center; and subcontract N01-AI-035173-117/412 with Johns 
Hopkins University. In addition, this work was supported by the HIV Pre-
vention Trials Network (HPTN) and sponsored by the National Institute of 
Allergy and Infectious Diseases, National Institute of Child Health and 
Human Development, National Institute on Drug Abuse, National Institute 
of Mental Health, and Office of AIDS Research, of the National Institutes of 
Health, U.S. Department of Health and Human Services, Harvard Univer-
sity (U01-AI-048006), Johns Hopkins University (U01-AI-048005), the Uni-
versity of Alabama at Birmingham (U01-AI-047972), and Family Health 
International (U01-AI-068619). Nevirapine (Viramune®) was provided for 
the HPTN024 protocol by Boehringer Ingelheim Pharmaceuticals, Inc. The 
conclusions and opinions expressed in this paper are those of the authors 
and do not necessarily reflect those of the funding agencies and participating 
institutions.
References
1. Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M: Approach to
the patient with anemia: Hematology and Oncologyin the Merck Manual of
Diagnosis and Therapy Volume Chapter 3. 18th edition. Issue Section 11
Merck Research Laboratories, Division of Merck & Co., Inc. White-
house Station NJ; 2006:1031-1033. 
2. Mukiibi JM, Mtimavalye LAR, Broadhead R, et al.: Some hematolog-
ical parameters in Malawian neonates.  East Afr Med J 1995,
72(1):10-14.
3. Miller MF, Stoltzfus RJ, Iliff PJ, et al.: Effect of maternal and neona-
tal vitamin A supplementation and other postnatal factors
on anemia in Zimbabwean infants: a prospective, rand-
omized study.  Am J Clin Nutr 2006, 84(1):212-222.
4. Quintó L, Aponte JJ, Sacarlal J, et al.: Hematological and biochem-
ical indices in young African children: in search of reference
intervals.  Trop Med Int Health 2006, 11(11):1741-1748.
5. Fleming AF, Harrison KA: Leukocyte counts during pregnancy
and the puerperium and at birth in Nigerians.  East Afr Med J
1985, 62(3):175-184.
6. Scott-Emuakpor AB, Okolo AA, Omene JA, Ukpe SI: Normal
Hematological Values in the African Neonate.  Blut 1985,
51(1):11-18.
7. Stancheva VP, Sherman GG, Avent M, Cory BJ, Ballot DE, Cooper PA:
Hematological reference ranges in black very low birth
weight infants.  Pediatr Hematol Oncol 2002, 19(2):91-94.
8. Taha TE, Kumwenda N, Gibbons A, et al.: Effect of HIV-1 antiret-
roviral prophylaxis on hepatic and hematological parame-
ters of African infants.  AIDS 2002, 16(6):851-858.
9. Lugada ES, Mermin J, Kaharuza F, et al.: Downing R: Population-
based hematologic and immunologic reference values for a
healthy Ugandan population.  Clin Diagn Lab Immunol 2004,
11(1):29-34.
10. Gomo E, Vennervald BJ, Ndhlovu P, Kaestel P, Nyazema N, Friis H:
Predictors and reference values of CD4 and CD8 T lym-
phocyte counts in pregnancy: a cross sectional study among
HIV-negative women in Zimbabwe.  Cent Afr J Med 2004, 50(1–
2):10-19.
11. Fawzi WW, Msamanga GI, Kupka R, et al.: Multivitamin supple-
mentation improves hematologic status in HIV-infected
women and their children in Tanzania.  Am J Clin Nutr 2007,
85(5):1335-1343.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pediatrics 2009, 9:49 http://www.biomedcentral.com/1471-2431/9/49
Page 14 of 14
(page number not for citation purposes)
12. Embree J, Bwayo J, Nagelkerke N, et al.: Lymphocyte subsets in
human immunodeficiency virus type 1-infected and unin-
fected children in Nairobi.  Pediatr Infect Dis J 2001,
20(4):397-403.
13. Moodley D, Bobat RA, Coovadia HM, Doorasamy T, Munsamy S,
Gouws E: Lymphocyte subset changes between 3 and 15
months of age in infants born to HIV-seropositive women in
South Africa.  Trop Med Int Health 1997, 2(5):415-421.
14. Taha TE, Brown ER, Hoffman IF, et al.: A phase III clinical trial of
antibiotics to reduce chorioamnionitis-related perinatal
HIV-1 transmission.  AIDS 2006, 20(9):1313-1321.
15. Devi SB, Singh KJ, Devi YL, Singh WG: Maternal and neonatal
anthropometric and haematological parameters in Manipuri
Population.  Indian Pediatr 1989, 26(7):673-677.
16. Erhabor O, Babatunde S, Uko K: Some hematological parame-
ters in plasmodial parasitized HIV-infected Nigerians.  Niger J
Med 2006, 15(1):52-55.
17. Geaghan SM: Appendix B, Normal blood values: Selected
health-associated values for neonatal, pediatric, and adult
populations.  In Wintrobe's Clinical Hematology 12th edition. Edited
by: Greer JP, Foerster J, Lukens JN, et al. Philadelphia: Lippincott Wil-
liams & Wilkins; 2009:2584-6. 
18. Ozyurek E, Cetintas S, Ceylan T, et al.: Complete blood count
parameters for healthy, small-for-gestational-age, full-term
newborns.  Clin Lab Haem 2006, 28(2):97-104.
19. Maconi M, Rolfo A, Cardaropoli S, Brini M, Danise P: Hematologi-
cal values in health and small for gestational age newborns.
Lab Hematol 2005, 11(2):152-156.
20. Marwaha N, Marwaha RK, Narang A, Thusu K, Garewal G, Bhakoo
ON: Routine haematological values in term newborns.  Indian
Pediatr 1992, 29(9):1095-1099.
21. Redźko S, Przepies ´ ć J, Zak J, Urban J, Wysocka J: Influence of peri-
natal factors on hematological variables in umbilical cord
blood.  J Perinat Med 2005, 33(1):42-45.
22. Chen RY, Westfall AO, Hardin JM, et al.: Complete blood cell
count as a surrogate CD4+ cell marker for HIV monitoring
in resource-limited settings.  J Acquir Immune Defic Syndr 2007,
44(5):525-530.
23. Mukiibi JM, Nkrumah FK, Kaur M, Akino V, Nhembe M: Neonatal
haematology in Zimbabwe. I: The platelet parameters.  Cent
Afr J Med 1994, 40(4):80-83.
24. Ogala WN: Platelet counts in healthy Nigerian neonates and
infants.  East Afr Med J 1986, 63(9):592-594.
25. Abdurrahman MB, Adekoje MA: Haematological values in
Northern Nigerian neonates.  Trans R Soc Trop Med Hyg 1983,
77(6):786-788.
26. Effiong CE, Usanga EA, Mellits ED: Platelet count in healthy full-
term Nigerian neonates.  Trop Geogr Med 1976, 28(4):329-332.
27. Modjarrad K, Chamot E, Vermund SH: Impact of small reductions
in plasma HIV RNA levels on the risk of heterosexual trans-
mission and disease progression.  AIDS 2008, 22(16):2179-2185.
28. Risk factors for mother-to-child transmission of HIV-1: European
Collaborative Study.  Lancet 1992, 339(8800):1007-1012.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2431/9/49/prepub